Clinical Trial Results: Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating siltuximab for treating cytokine release syndrome and ICANS associated with CAR-T cell therapy; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Cytokine Release Syndrome
• Immune Effector Cell Associated Neurotoxicity
• Lymphoma Non-hodgkin
• Multiple Myeloma

Drugs mentioned

• Siltuximab (siltuximab)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Cytokine Release Syndrome, ICANS | Phase 2 | Status: COMPLETED | Results posted: 2026-06-03